Page 51 - Lipids News Today

Researchers have long been working on how to treat obesity, a serious condition that can lead to hypertension, diabetes, chronic inflammation, and cardiovascular diseases.

The standard risk calculator requires nine variables, and not all of them are always available in the EHR. The proposed CXR model has performed similarly to the standard model.

Electronic nudges that promote new statin prescriptions seemed most effective when sent to patients as well as their primary care doctors in a randomized trial.

Higher levels of lipoprotein(a) are associated with risk similar to that seen with familial hypercholesterolemia, but with risk starting as low as an Lp(a) of 70 mg/dL, new data suggest.

Envomed, the brand behind the Envomed80 on-site medical waste treatment solution, has appointed Hagai Yehidi as its new CEO.

From timing of medications to supplement use, Dr Anne Peters reviews several recent studies that have changed beliefs in the realm of cardiovascular disease.

A substudy of the VITAL trial provides the first randomized data examining the effect of the popular supplement on muscle symptoms in statin users.

At a conference in Spain, researchers discussed the potential cardiometabolic effect of the treatment, as well as unresolved questions about its efficacy in obesity.

Insulin delivery devices have evolved drastically since their invention in 1922. They are all aimed to provide insulin to the patients with minimal discomfort.

A large, biracial cohort study found that low levels of high-density lipoprotein cholesterol dont raise heart disease risk in Black patients.